Priority list identifies drugs needing evidence for off-label use in US
This article was originally published in SRA
Executive Summary
In an effort to tighten up the scientific rationale for off-label prescribing of medicines in the US, a research group has drawn up a priority list of 14 drugs most urgently in need of additional study to determine their efficacy and safety in these uses1.